Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Non-Current Debt: 2024

Historic Non-Current Debt for Apellis Pharmaceuticals (APLS) over the last 1 years, with Dec 2024 value amounting to $359.5 million.

  • Apellis Pharmaceuticals' Non-Current Debt rose 0.59% to $361.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $361.1 million, marking a year-over-year increase of 0.59%. This contributed to the annual value of $359.5 million for FY2024, which is N/A change from last year.
  • Apellis Pharmaceuticals' Non-Current Debt amounted to $359.5 million in FY2024.
  • In the past 5 years, Apellis Pharmaceuticals' Non-Current Debt ranged from a high of $359.5 million in FY2024 and a low of $359.5 million during FY2024.
  • Moreover, its 1-year median value for Non-Current Debt was $359.5 million (2024), whereas its average is $359.5 million.